TY  - JOUR
AU  - Philis-Tsimikas, Athena
AU  - Billings, Liana K
AU  - Busch, Robert
AU  - Portillo, Cristobal Morales
AU  - Sahay, Rakesh
AU  - Halladin, Natalie
AU  - Eggert, Sarah
AU  - Begtrup, Kamilla
AU  - Harris, Stewart
PY  - 2019
DO  - 10.1111/dom.13666
UR  - http://hdl.handle.net/10668/13562
T2  - Diabetes, obesity & metabolism
AB  - To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. In this 26-week, phase IIIb, open-label,...
LA  - en
KW  - GLP-1 analogue
KW  - SGLT2 inhibitor
KW  - insulin therapy
KW  - liraglutide
KW  - randomized trial
KW  - type 2 diabetes
KW  - Aged
KW  - Diabetes Mellitus, Type 2
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Female
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Insulin, Long-Acting
KW  - Liraglutide
KW  - Male
KW  - Middle Aged
KW  - Sodium-Glucose Transporter 2 Inhibitors
TI  - Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
TY  - research article
VL  - 21
ER  -